drugset / Trial / NCT07311408
SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
RandomizedParallel-groupOpen-labelTreatment
Summary
To investigate the efficacy of SHR-1701 combined with Rivoceranib, with or without SHR-2554, in patients with gastric or gastroesophageal junction adenocarcinoma who have progressed on or were intolerant to first-line immunotherapy-containing treatment
Timeline
- Start
- 2026-01-01
- Primary completion
- 2028-01-01
- Completion
- 2029-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | Intravenous |
| Subject | Rivoceranib | Small molecule | — | Oral |
| Comparator | SHR2554 | Small molecule | — | Oral |